» Articles » PMID: 20220779

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2010 Mar 12
PMID 20220779
Citations 153
Authors
Affiliations
Soon will be listed here.
Abstract

To gain insight into the molecular pathogenesis of the myelodysplastic syndromes (MDS), we performed global gene expression profiling and pathway analysis on the hematopoietic stem cells (HSC) of 183 MDS patients as compared with the HSC of 17 healthy controls. The most significantly deregulated pathways in MDS include interferon signaling, thrombopoietin signaling and the Wnt pathways. Among the most significantly deregulated gene pathways in early MDS are immunodeficiency, apoptosis and chemokine signaling, whereas advanced MDS is characterized by deregulation of DNA damage response and checkpoint pathways. We have identified distinct gene expression profiles and deregulated gene pathways in patients with del(5q), trisomy 8 or -7/del(7q). Patients with trisomy 8 are characterized by deregulation of pathways involved in the immune response, patients with -7/del(7q) by pathways involved in cell survival, whereas patients with del(5q) show deregulation of integrin signaling and cell cycle regulation pathways. This is the first study to determine deregulated gene pathways and ontology groups in the HSC of a large group of MDS patients. The deregulated pathways identified are likely to be critical to the MDS HSC phenotype and give new insights into the molecular pathogenesis of this disorder, thereby providing new targets for therapeutic intervention.

Citing Articles

The rewired immune microenvironment in leukemia.

Ciantra Z, Paraskevopoulou V, Aifantis I Nat Immunol. 2025; 26(3):351-365.

PMID: 40021898 DOI: 10.1038/s41590-025-02096-9.


Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.

Gharaee N, Wegrzyn-Woltosz J, Jiang J, Akhade V, Bridgers J, Stubbins R Leukemia. 2025; .

PMID: 40000845 DOI: 10.1038/s41375-025-02537-2.


Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances.

Thalambedu N, Mohan Lal B, Harbaugh B, Alapat D, Gaddam M, Gentille Sanchez C Cancers (Basel). 2025; 17(3).

PMID: 39941875 PMC: 11816122. DOI: 10.3390/cancers17030508.


MSI2 mediates WNT/β-Catenin pathway function in hematopoietic stem cells.

Zhang H, Guo R, Li Z, Ma R, Xu S, Yin L Leukemia. 2024; 39(1):265-270.

PMID: 39438589 DOI: 10.1038/s41375-024-02447-9.


Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response.

Gonzalez M, Chakraborty S, Hernandez-Sanchez J, Diez Campelo M, Park C, Hernandez Rivas J Front Oncol. 2024; 14:1438052.

PMID: 39376992 PMC: 11456566. DOI: 10.3389/fonc.2024.1438052.